A Targeted Therapy Next in Line for Biomarker-based Cancer Drug Approval?
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...
There is perhaps nothing more painful for parents than receiving a cancer diagnosis for their child. Childhood cancers are...
In recent years, the American Association for Cancer Research (AACR) has expanded its efforts to catalyze advances in cancer...
A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput...
Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate...
Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers...
Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with...
A hot topic in the field of cancer immunotherapy is: How do some cancers that initially respond to immune...
The next step in trying to increase the proportion of patients who respond to these therapies, therefore, is to...
A team of researchers from Australia has shown that an optical fiber-tip probe that can detect the pH of...